Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-12-12

Clinical Trial Update: The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093 [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated tolerability and how food affects the pharmacokinetics of a single 800 mg oral dose of BIA 2-093 in epilepsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BIA 2-093

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Epilepsy | Phase 1 | Status: COMPLETED | Results posted: 2014-12-12